Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells Journal Article

  


Authors: Shimazaki, C.; Atzpodien, J.; Wisniewski, D.; Gulati, S. C.; Kolitz, J. E.; Fried, J.; Clarkson, B. D.
Article Title: Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells
Abstract: We studied the sensitivity of human myeloma (plasma cell leukemia) toward autologous and allogeneic lymphokine-activated killer (LAK) cells. Fresh plasma cell leukemia (PCL)-derived peripheral blood mononuclear cells (PBMC) and PBMC from 3 normal donors were cultured in the presence of recombinant interleukin-2 (rIL2; 1, 000 U/ml) for subsequent use as cytotoxic effectors against fresh and continuously cultured myeloma cells. Target cell lysis was measured in a 4-hour5lCr radioisotope release assay. At an effector to target (E: T) ratio of 50:1, rIL2-induced PCL-PBMC lysed 48 ± 19% (mean ± 1 SD) of autologous myeloma targets, as compared to 89 ±5, 95 ± 15, and 100 ±9% lysis of standard LAK-sensitive Daudi cells and allogeneic myeloma cell lines SKO-007, and RPMI-8226, respectively. Normal PBMC-derived rIL2-induced (LAK) cells exhibited a slightly lower cytotoxic reactivity against allogeneic targets (61 ±9, 60 ±6, and 81 ± 8% cytolysis of SKO-007, RPMI-8226, and Daudi cells, respectively, at a 50:1 E:T ratio). Cytotoxicity against myeloma (PCL) of autologous PCL-derived killer cells could be significantly (at least 2-fold) enhanced when rIL-2- induced effector cells were preincubated for 18 h in the presence of recombinant Interferon-αa rIFN-α; 1, 000 U/ml). In summary, our results indicate the potential antitumor efficacy of rIL2- and rIL2 + rlFN-α-activated killer cells in human myeloma (PCL). © 1988 S. Karger AG, Basel.
Keywords: phenotype; cells, cultured; interleukin 2; multiple myeloma; cytotoxicity; lymphocyte activation; gamma interferon; cell culture; interferon-gamma, recombinant; recombinant proteins; cytotoxicity, immunologic; myeloma; interleukin-2; immunity, cellular; interferon-α; cytotoxicity tests, immunologic; chromium 51; interferon type i, recombinant; lymphokine activated killer cell; human; priority journal; killer cells; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; lymphokine-activated killer cells
Journal Title: Acta Haematologica
Volume: 80
Issue: 4
ISSN: 0001-5792
Publisher: S. Karger AG  
Date Published: 1988-01-01
Start Page: 203
End Page: 209
Language: English
DOI: 10.1159/000205638
PUBMED: 3146198
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024202663&doi=10.1159%2f000205638&partnerID=40&md5=ddd0f9f478f02ade119530c8be722c57
Notes: Article -- Export Date: 6 August 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David Wisniewski
    37 Wisniewski
  2. Bayard Clarkson
    220 Clarkson
  3. Subhash C. Gulati
    129 Gulati
  4. Jonathan E. Kolitz
    21 Kolitz
  5. Jens Atzodien
    24 Atzodien
Related MSK Work